-
1
-
-
84971581087
-
Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
-
Non-small Cell Lung Cancer Collaborative Group
-
Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311:899-909.
-
(1995)
BMJ
, vol.311
, pp. 899-909
-
-
-
2
-
-
0035195364
-
Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: Review of literature results
-
Klastersky J, Paesmans M. Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results. Lung Cancer 2001; 34(suppl 4):S95-S101.
-
(2001)
Lung Cancer
, vol.34
, Issue.SUPPL. 4
-
-
Klastersky, J.1
Paesmans, M.2
-
3
-
-
0029033213
-
Management (chemotherapy/best supportive care) of advanced-stage non-small cell lung cancer
-
Carney DN. Management (chemotherapy/best supportive care) of advanced-stage non-small cell lung cancer. Semin Oncol 1995; 22(suppl 9):58-62.
-
(1995)
Semin Oncol
, vol.22
, Issue.SUPPL. 9
, pp. 58-62
-
-
Carney, D.N.1
-
4
-
-
0037842153
-
Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: Results from Eastern Cooperative Oncology Group study 5592
-
Eton DT, Fairclough DL, Celia D, et al. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group study 5592. J Clin Oncol 2003; 21:1536-1543.
-
(2003)
J Clin Oncol
, vol.21
, pp. 1536-1543
-
-
Eton, D.T.1
Fairclough, D.L.2
Celia, D.3
-
5
-
-
0037050352
-
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
-
Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98.
-
(2002)
N Engl J Med
, vol.346
, pp. 92-98
-
-
Schiller, J.H.1
Harrington, D.2
Belani, C.P.3
-
6
-
-
0030297662
-
A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer
-
Fujino S, Enokibori T, Tezuka N, et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer 1996; 32A:2070-2074.
-
(1996)
Eur J Cancer
, vol.32 A
, pp. 2070-2074
-
-
Fujino, S.1
Enokibori, T.2
Tezuka, N.3
-
7
-
-
0027170357
-
Evidence for a role of EGF receptor in the progression of human lung carcinoma
-
Pavelic K, Banjac Z, Pavelic J, et al. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 1993; 13:1133-1138.
-
(1993)
Anticancer Res
, vol.13
, pp. 1133-1138
-
-
Pavelic, K.1
Banjac, Z.2
Pavelic, J.3
-
8
-
-
0012381722
-
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
-
Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:2237-2246.
-
(2003)
J Clin Oncol
, vol.21
, pp. 2237-2246
-
-
Fukuoka, M.1
Yano, S.2
Giaccone, G.3
-
9
-
-
0142055937
-
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial
-
Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 2003; 290:2149-2158.
-
(2003)
JAMA
, vol.290
, pp. 2149-2158
-
-
Kris, M.G.1
Natale, R.B.2
Herbst, R.S.3
-
10
-
-
4344646459
-
Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer
-
Perez-Soler R, Chachuoa A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22:3238-3247.
-
(2004)
J Clin Oncol
, vol.22
, pp. 3238-3247
-
-
Perez-Soler, R.1
Chachuoa, A.2
Hammond, L.A.3
-
11
-
-
12744255161
-
Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer
-
Perez-Soler R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer 2004; 6(suppl 1):S20-S23.
-
(2004)
Clin Lung Cancer
, vol.6
, Issue.SUPPL. 1
-
-
Perez-Soler, R.1
-
12
-
-
0034069620
-
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
-
Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095-2103.
-
(2000)
J Clin Oncol
, vol.18
, pp. 2095-2103
-
-
Shepherd, F.A.1
Dancey, J.2
Ramlau, R.3
-
13
-
-
23844438017
-
Results from a phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer
-
on behalf of the SIGN study group. (Abstract #7035)
-
Cufer T, Vrdoljak E, on behalf of the SIGN study group. Results from a phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. J Clin Oncol 2005; 23:629s (Abstract #7035).
-
(2005)
J Clin Oncol
, vol.23
-
-
Cufer, T.1
Vrdoljak, E.2
-
14
-
-
1542503746
-
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1
-
Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004; 22:777-784.
-
(2004)
J Clin Oncol
, vol.22
, pp. 777-784
-
-
Giaccone, G.1
Herbst, R.S.2
Manegold, C.3
-
15
-
-
1542713370
-
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2
-
Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2.J Clin Oncol 2004; 22:785-794.
-
(2004)
J Clin Oncol
, vol.22
, pp. 785-794
-
-
Herbst, R.S.1
Giaccone, G.2
Schiller, J.H.3
-
16
-
-
4444238981
-
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
-
(Abstract #7010)
-
Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23:617 (Abstract #7010).
-
(2004)
Proc Am Soc Clin Oncol
, vol.23
, pp. 617
-
-
Gatzemeier, U.1
Pluzanska, A.2
Szczesna, A.3
-
17
-
-
24944440830
-
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
-
Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892-5899.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5892-5899
-
-
Herbst, R.S.1
Prager, D.2
Hermann, R.3
-
18
-
-
27544503230
-
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
-
Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-1537.
-
(2005)
Lancet
, vol.366
, pp. 1527-1537
-
-
Thatcher, N.1
Chang, A.2
Parikh, P.3
-
19
-
-
1242283946
-
Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer
-
Argiris A, Mittal N. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung Cancer 2004; 43:317-322.
-
(2004)
Lung Cancer
, vol.43
, pp. 317-322
-
-
Argiris, A.1
Mittal, N.2
-
20
-
-
85030607424
-
Outcome of 48 patients with advanced non small cell lung cancer (NSCLC) receiving gefitinib monotherapy after failing prior chemotherapy or as initial therapy
-
(Abstract #2837)
-
Nableh Z, Abdalla I, Kinsella V, et al. Outcome of 48 patients with advanced non small cell lung cancer (NSCLC) receiving gefitinib monotherapy after failing prior chemotherapy or as initial therapy. Proc Am Soc Clin Oncol 2003; 22:705 (Abstract #2837).
-
(2003)
Proc Am Soc Clin Oncol
, vol.22
, pp. 705
-
-
Nableh, Z.1
Abdalla, I.2
Kinsella, V.3
-
21
-
-
3042747669
-
Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience
-
Kommareddy A, Coplin MA, Gao F, et al. Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience. Lung Cancer 2004; 45:221-225.
-
(2004)
Lung Cancer
, vol.45
, pp. 221-225
-
-
Kommareddy, A.1
Coplin, M.A.2
Gao, F.3
-
22
-
-
85030599642
-
Cancer Therapy Evaluation Programs (CTEP). Common Toxicity Criteria v2.0
-
National Cancer Institute. Bethesda, MD: Division of Cancer Treatment and Diagnosis, National Cancer Institute; 1999. Available at Accessed April 10
-
National Cancer Institute. Cancer Therapy Evaluation Programs (CTEP). Common Toxicity Criteria v2.0. Bethesda, MD: Division of Cancer Treatment and Diagnosis, National Cancer Institute; 1999. Available at: http://ctep.cancer.gov/reporting/ctc.html. Accessed April 10, 2003.
-
(2003)
-
-
-
23
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors
-
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
24
-
-
2342624080
-
EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
-
Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500.
-
(2004)
Science
, vol.304
, pp. 1497-1500
-
-
Paez, J.G.1
Jänne, P.A.2
Lee, J.C.3
-
25
-
-
20244389188
-
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
-
Han S-W, Kim T-Y, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23:2493-2501.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2493-2501
-
-
Han, S.-W.1
Kim, T.-Y.2
Hwang, P.G.3
-
26
-
-
17844390172
-
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions
-
Pao W Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005; 23:2556-2568.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2556-2568
-
-
Pao, W.1
Miller, V.A.2
-
27
-
-
31544440171
-
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer
-
Shih J-Y, Gow C-H, Yu C-J, et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 2006; 118:963-969.
-
(2006)
Int J Cancer
, vol.118
, pp. 963-969
-
-
Shih, J.-Y.1
Gow, C.-H.2
Yu, C.-J.3
-
28
-
-
20444498630
-
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
-
Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97:643-655.
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 643-655
-
-
Cappuzzo, F.1
Hirsch, F.R.2
Rossi, E.3
-
29
-
-
24644445676
-
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients
-
Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 2005; 23:5007-5018.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5007-5018
-
-
Cappuzzo, F.1
Varella-Garcia, M.2
Shigematsu, H.3
-
30
-
-
33745906000
-
Phase II trial of first-line gefitinib in patients unsuitable for chemotherapy with stage III/IV non-small-cell lung cancer
-
(Abstract #7256)
-
Swinson D, Williams S, Beddard K, et al. Phase II trial of first-line gefitinib in patients unsuitable for chemotherapy with stage III/IV non-small-cell lung cancer. J Clin Oncol 2005; 23:684s (Abstract #7256).
-
(2005)
J Clin Oncol
, vol.23
-
-
Swinson, D.1
Williams, S.2
Beddard, K.3
-
31
-
-
17144385106
-
Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers
-
Lee DH, Han JY, Lee HG, et al. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 2005; 11:3032-3037.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 3032-3037
-
-
Lee, D.H.1
Han, J.Y.2
Lee, H.G.3
|